生物
内源性逆转录病毒
干扰素
TLR3型
癌症研究
DNA甲基化
Ⅰ型干扰素
下调和上调
核糖核酸
免疫检查点
免疫系统
基因
分子生物学
RNA沉默
免疫学
先天免疫系统
基因表达
RNA干扰
免疫疗法
遗传学
Toll样受体
基因组
作者
Katherine B. Chiappinelli,Pamela L. Strissel,Alexis Desrichard,Huili Li,Christine Henke,Benjamin Akman,Alexander Hein,Neal S. Rote,Leslie Cope,Alexandra Snyder,Vladimir Makarov,Sadna Buhu,Dennis J. Slamon,Jedd D. Wolchok,Drew M. Pardoll,Matthias W. Beckmann,Cynthia A. Zahnow,Taha Merghoub,Timothy A. Chan,Stephen B. Baylin,Reiner Strick
出处
期刊:Cell
[Cell Press]
日期:2015-08-01
卷期号:162 (5): 974-986
被引量:1642
标识
DOI:10.1016/j.cell.2015.07.011
摘要
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
科研通智能强力驱动
Strongly Powered by AbleSci AI